Using Azacitidine to Prevent Kidney Damage After Surgery
Study of the Effect of Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum
PHASE1; PHASE2 · National Taiwan University Hospital · NCT05325099
This study tests if the drug azacitidine can help prevent kidney damage in patients who have had heart surgery by targeting specific cells that contribute to kidney problems.
Quick facts
| Phase | PHASE1; PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital (other) |
| Locations | 1 site (Taipei) |
| Trial ID | NCT05325099 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of azacitidine, a demethylating agent, to prevent the progression from acute kidney injury (AKI) to chronic kidney disease (CKD) in patients who have undergone cardiac surgery. The study focuses on understanding the role of pericytes, which are cells involved in kidney scarring, and how their epigenetic modifications contribute to kidney damage. By administering azacitidine, the researchers aim to reverse these modifications and reduce fibrogenesis, potentially improving kidney outcomes for affected patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have experienced stage 2 or stage 3 acute kidney injury following cardiac surgery.
Not a fit: Patients with chronic kidney disease or other serious conditions such as decompensated heart failure or active cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the risk of chronic kidney disease in patients recovering from acute kidney injury.
How similar studies have performed: While the approach of using azacitidine for this purpose is novel, previous studies have indicated potential benefits of targeting epigenetic modifications in kidney injury.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with cardiac surgery associated-AKI, stage 2 and stage 3 Exclusion Criteria: * Chronic kidney disease * Decompensated heart failure (EF \< 45%) * Liver cirrhosis, child B or C * Acute infection * Acute bleeding * Long-term use of immunosuppressant other than azacitidine * Patients with active cancer other than acute leukemia or myelodysplastic syndrome * Leukopenia, anemia or thrombocytopenia * Pregnancy
Where this trial is running
Taipei
- Yu Hsiang Chou — Taipei, Taiwan (RECRUITING)
Study contacts
- Principal investigator: Yu Hsiang Chou, PhD — National Taiwan University Hospital
- Study coordinator: Yu Hsiang Chou, PhD
- Email: chouyuhsiang11@gmail.com
- Phone: 886-23123456
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Acute Kidney Disease